Development of voluntary private health insurance in Nordic countries – An exploratory study on country-specific contextual factors
The Nordic welfare state ethos starts with the idea that distribution of healthcare resources should be based on individual needs, not on the ability to pay. Despite this, there has been a significant expansion of voluntary private health insurance (VPHI) contracts during the recent decade (Table 1). In terms of healthcare financing, the contribution of VPHI is small [2,5] but the number of people with VPHIs has increased rapidly. This expansion is challenging because VPHI is primarily available to individuals with higher socioeconomic status and better health [2,6]. (Source: Health Policy)
Source: Health Policy - March 16, 2018 Category: Health Management Authors: Liina-Kaisa Tynkkynen, Nina Alexandersen, Oddvar Kaarb øe, Anders Anell, Juhani Lehto, Karsten Vrangbӕk Source Type: research
Development of Voluntary Private Health Insurance in Nordic Countries − An Exploratory Study on Country-specific Contextual Factors
(Source: Health Policy)
Source: Health Policy - March 16, 2018 Category: Health Management Authors: Liina-Kaisa Tynkkynen, Nina Alexandersen, Oddvar Kaarb øe, Anders Anell, Juhani Lehto, Karsten Vrangbӕk Source Type: research
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus
Rare diseases are an important public health issue and a challenge for the medical community, not only due to the clinical and therapeutic complexity they represent, but also because of the lack of knowledge regarding their natural course, which jeopardises prompt diagnosis and the anticipation of serious risks with undesirable outcomes [1]. Although rare diseases affect a limited number of persons, defined in the European Union as 1 in 2000 individuals or less [2], according to the World Health Organisation, between 5000 and 8000 disorders are defined as “rare” [3]. (Source: Health Policy)
Source: Health Policy - March 15, 2018 Category: Health Management Authors: J. Torrent-Farnell, M. Comellas, J.L. Poveda, I. Abaitua, L.G. Guti érrez-Solana, J. Pérez-López, J. Cruz, J. Urcelay, L. Lizán Source Type: research
The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: a Delphi consensus
(Source: Health Policy)
Source: Health Policy - March 15, 2018 Category: Health Management Authors: J. Torrent-Farnell, M. Comellas, J.L. Poveda, I. Abaitua, L.G. Guti érrez-Solana, J. Pérez-López, J. Cruz, J. Urcelay, L. Lizán Source Type: research
Experts ’ perspectives on SwissDRG: Second class care for vulnerable patient groups?
With the introduction of the Swiss diagnosis-related group (DRG) hospital in-patient payment system as of January 2012, the Swiss Federal Council aimed to create an incentive to contain the increasing cost of healthcare [1]. This new tariff structure forces hospitals to produce economically efficient outcomes by reducing the length of stay and the number of services provided as well as maximizing the number of (profitable) cases [2 –4]. Scholars and healthcare professionals have feared that its introduction would decrease the quality of care provided to patients, particularly those who would fall within the less profitab...
Source: Health Policy - March 14, 2018 Category: Health Management Authors: A. Leu, H. Wepf, B. Elger, T. Wangmo Source Type: research
Does multimorbidity still remain a matter of the elderly: Lithuanian national data analysis
Multimorbidity, which is defined as the presence of two or more chronic conditions at the same time, has become recognized as the most common medical status [1]. It is clear that the paradigm of “1 patient and 1 disease” no longer fits the medical necessities and needs of most patients, and a more holistic, patient-centered view needs to be developed [2–5]. It is well-known that the proportion of patients with more than one chronic condition increases with age hitting 85% in over 85 year olds [5]. (Source: Health Policy)
Source: Health Policy - March 14, 2018 Category: Health Management Authors: E. Jurevi čienė, G. Onder, Ž. Visockienė, R. Puronaitė, D. Petrikonytė, U. Gargalskaitė, V. Kasiulevičius, R. Navickas Source Type: research
Testing a new taxonomic model for the assessment of medical devices: Is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe
Europe is one of the biggest markets for Medical devices (MDs), which encompass a broad and heterogeneous range of technologies. They include ‘[…] any instrument, apparatus, appliance, software, implant, reagent, material or other article intended by the manufacturer to be used, alone or in combination, for human beings for one or more of the following specific medical purposes: diagnosis, prevention, monitoring, prediction, prognosis , treatment or alleviation of disease […]’ [1]. To date, several classification systems for MDs have been developed, ranging from those aiming to facilitate market approval by categor...
Source: Health Policy - March 14, 2018 Category: Health Management Authors: Sabine Fuchs, Britta Olberg, Matthias Perleth, Reinhard Busse, Dimitra Panteli Source Type: research
Experts ’ perspectives on SwissDRG: second class care for vulnerable patient groups?
(Source: Health Policy)
Source: Health Policy - March 14, 2018 Category: Health Management Authors: A. Leu, H. Wepf, B. Elger, T. Wangmo Source Type: research
Does multimorbidity still remain a matter of the elderly: Lithuanian national data analysis
(Source: Health Policy)
Source: Health Policy - March 14, 2018 Category: Health Management Authors: E. Jurevi čienė, G. Onder, Ž. Visockienė, R. Puronaitė, D. Petrikonytė, U. Gargalskaitė, V. Kasiulevičius, R. Navickas Source Type: research
Testing a new taxonomic model for the assessment of medical devices: is it plausible and applicable? Insights from HTA reports and interviews with HTA institutions in Europe
(Source: Health Policy)
Source: Health Policy - March 14, 2018 Category: Health Management Authors: Sabine Fuchs, Britta Olberg, Matthias Perleth, Reinhard Busse, Dimitra Panteli Source Type: research
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
Global medicines expenditure is forecast to reach USD $1.4 trillion annually by 2020 [1], an increase of approximately 30% from 2015 levels. Given this upward pressure on healthcare budgets, balancing total spend on pharmaceuticals with the imperative to provide timely access to new medicines will be a critical priority for policy-makers. In the major European markets (France, Italy, Germany, Spain and the UK), payers, including both statutory organisations with delegated authority and compulsory/statutory health insurers, are expected to be at the forefront of finding solutions for optimising expenditure on medicines. (Source: Health Policy)
Source: Health Policy - March 8, 2018 Category: Health Management Authors: William C.N. Dunlop, Alexandra Staufer, Pierre Levy, Guy J. Edwards Source Type: research
Taking stock of Roma health policies in Spain: Lessons for health governance
The Roma have considerably poorer health outcomes when compared to non-Roma populations across Europe [1,2]. Studies point to a persistent health gap with Roma experiencing lower vaccination coverage, higher levels of communicable and non-communicable diseases, higher unmet health needs and higher infant mortality rates, while acknowledging definitional and methodological challenges that limit data comparibility and impact the depth of the evidence base [1,3 –8]. In 2005, twelve European countries joined efforts to promote Roma health equity through the Decade of Roma Inclusion – a political commitment to tackle the ro...
Source: Health Policy - March 8, 2018 Category: Health Management Authors: M. Escobar-Ballesta, M. Garc ía-Ramírez, C. De Freitas Source Type: research
Innovative pharmaceutical pricing agreements in five European markets: A survey of stakeholder attitudes and experience
(Source: Health Policy)
Source: Health Policy - March 8, 2018 Category: Health Management Authors: William C.N. Dunlop, Alexandra Staufer, Pierre Levy, Guy J. Edwards Source Type: research
Taking stock of Roma health policies in Spain: Lessons for health governance
(Source: Health Policy)
Source: Health Policy - March 8, 2018 Category: Health Management Authors: M. Escobar-Ballesta, M. Garc ía-Ramírez, C. De Freitas Source Type: research
